ZilucoplanComplement C5 inhibitor
Zilucoplan targets complement, part of the immune system that can damage the nerve–muscle junction in a specific form of myasthenia gravis. It is not a muscle-building treatment.
What is Zilucoplan?
Zilucoplan is a complement C5 inhibitor. In the EU it is an add-on treatment for adults with generalised myasthenia gravis who have anti-acetylcholine-receptor antibodies. 3
How it works
It inhibits the C5 stage of complement activation, targeting a pathway that contributes to injury at the neuromuscular junction.
Effects studied
Daily function in generalised myasthenia gravis
A 12-week study involving 174 participants found a larger average improvement in a daily-activity scale than placebo. 3
Evidence: Randomised evidence in a defined antibody-positive population, alongside background care.
What does the evidence show?
Randomised myasthenia trial and EMA assessment
The problem is communication with muscle
In myasthenia gravis, immune activity disrupts transmission between nerves and muscles. Some patients have antibodies against the acetylcholine receptor. Complement activation contributes to damage at that junction, creating a treatment target quite different from muscle size, training adaptation or nutritional deficiency.
What zilucoplan blocks
Zilucoplan inhibits complement protein C5, reducing downstream immune damage. The EU assessment concerns add-on use in adults with generalised myasthenia gravis who have acetylcholine-receptor antibodies. Its benefit needs to be understood within that specific antibody and disease context. 3
What improvement meant in the trial
The main study followed 174 participants for 12 weeks and used a scale covering daily activities affected by myasthenia. Zilucoplan produced a larger average improvement than placebo. This supports a specific symptom and function benefit; it does not mean the underlying autoimmune condition has disappeared. 3
Blocking defence changes infection risk
Complement also helps defend against certain infections. Meningococcal infection is a major concern, making preventive measures and rapid assessment of symptoms essential parts of specialist care. Injection-site reactions and respiratory infections are also described in the assessment. These risks and precautions need to be weighed alongside the potential benefit. 3
Safety & status
Complement inhibition creates an important meningococcal-infection risk requiring preventive measures. Injection-site and respiratory-infection events are also described in the EMA information. 3
Country and product status
EU indication checked: add-on treatment of generalised myasthenia gravis in anti-AChR-positive adults. Swiss status not checked.
Frequently asked questions
Is it used for every type of muscle weakness?
No. Its indication concerns a defined form of antibody-positive generalised myasthenia gravis. 3
Does it replace all existing treatment?
The EU indication is as an add-on treatment, not a universal substitute for other care. 3
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
- EMA · Zilbrysq assessment Primary source checked · Checked 27 October 2026: EU population, mechanism, 174-person trial and meningococcal infection risk.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.